bioAffinity reports CyPath Lung test volume up 111% in Oct vs 2025 monthly avg

bioAffinity Technologies, Inc.

October test volume increased 111% over 2025 monthly average; Q3 volume rose 95% sequentially.
Medical practices with multiple CyPath orders rose 106% QoQ in Q3 and 67% in Oct vs YTD monthly avg.
CyPath Lung noninvasive sputum test uses AI/flow cytometry; clinical study showed 92% sensitivity, 87% specificity.
CEO Maria Zannes cites growing physician trust and successful outreach to pulmonologists, health systems, VA centers.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.